IgA Nephropathy Clinical Trials in Houston, Texas
6 recruitingHouston, Texas
Showing 1–6 of 6 trials
Recruiting
Phase 2
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
IgA Nephropathy (IgAN)IgANC3G+2 more
ADARx Pharmaceuticals, Inc.45 enrolled25 locationsNCT06989359
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Primary IgA Nephropathy
Hoffmann-La Roche428 enrolled202 locationsNCT05797610
Recruiting
Phase 1
Study of BHV-1400 in IgA Nephropathy
IgA Nephropathy
Biohaven Therapeutics Ltd.20 enrolled12 locationsNCT07054684
Recruiting
Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
Phase 4
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
IgA Nephropathy
Calliditas Therapeutics AB60 enrolled38 locationsNCT06712407
Recruiting
Phase 2
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
IgA Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.25 enrolled5 locationsNCT06740526